In Models 2 and Model 3, the association between evolocumab use and discharge mRS of 0–3 was marginally significant (adjusted OR 2.02, 95% CI 0.97–4.24, p = 0.06 and adjusted OR 1.98, 95% CI 0.94–4.22, p = 0.07, respectively).
Evolocumab users showed a trend toward better outcomes with a higher proportion of patients achieving a mRS of 0–2 and lower mortality (55.0% vs. 39.2, and 7.5% vs. 19.1%, respectively) ( Figure 1B ); however, the differences were statistically insignificant ( p = 0.06 and 0.08, respectively).
First, the small number of patients treated with evolocumab at our center constrains the statistical power, resulting in only a trend toward significance after adjustment.